DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Primary Hyperoxaluria market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Primary Hyperoxaluria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Hyperoxaluria Market Insights

Primary Hyperoxaluria Overview

Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.

Some of the key facts of the Primary Hyperoxaluria Market Report: 

• The Primary Hyperoxaluria market size was valued approximately USD 80 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Total prevalent population of Primary Hyperoxaluria in 7MM was 11,948 in 2021 which is expected to increase by 2032
• The US accounted for highest prevalent population of Primary Hyperoxaluria among 7MM with 8,773 cases in 2021 which is expected to increase by 2032
• The estimates suggest higher diagnosed prevalence of Primary Hyperoxaluria In the United States with 2,327 diagnosed cases in 2021 which is expected to increase by 2032
• The estimates suggest higher diagnosed prevalence of PH Type 1 throughout the 7MM. In the US, out of total diagnosed prevalent cases of Primary Hyperoxaluria; 1,629 were occupied by Primary Hyperoxaluria Type 1 alone, in the year 202
• Key Primary Hyperoxaluria Companies: Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, and others
• Key Primary Hyperoxaluria Therapies: Nedosiran (DCR-PHXC), ALLN-177, Stiripentol, and others
• The Primary Hyperoxaluria epidemiology based on gender analyzed that males contributes to higher diagnosed prevalent cases as compared to females

Get a Free sample for the Primary Hyperoxaluria Market Report – 

https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market

Key benefits of the Primary Hyperoxaluria Market report:

1. Primary Hyperoxaluria market report covers a descriptive overview and comprehensive insight of the Primary Hyperoxaluria Epidemiology and Primary Hyperoxaluria market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Primary Hyperoxaluria market report provides insights on the current and emerging therapies.
3. Primary Hyperoxaluria market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Primary Hyperoxaluria market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Primary Hyperoxaluria market.

Download the report to understand which factors are driving Primary Hyperoxaluria epidemiology trends @ Primary Hyperoxaluria Epidemiological Insights

Primary Hyperoxaluria Market  

The dynamics of the Primary Hyperoxaluria market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Primary Hyperoxaluria Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Primary Hyperoxaluria Epidemiology Segmentation:

The Primary Hyperoxaluria market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Primary Hyperoxaluria
• Prevalent Cases of Primary Hyperoxaluria by severity
• Gender-specific Prevalence of Primary Hyperoxaluria
• Diagnosed Cases of Episodic and Chronic Primary Hyperoxaluria

Primary Hyperoxaluria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Hyperoxaluria market or expected to get launched during the study period. The analysis covers Primary Hyperoxaluria market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Primary Hyperoxaluria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Primary Hyperoxaluria market share @ Primary Hyperoxaluria market forecast

Primary Hyperoxaluria Therapies and Key Companies

• Nedosiran (DCR-PHXC): Dicerna Pharmaceuticals, Inc.
• ALLN-177: Allena Pharmaceuticals
• Stiripentol: Biocodex

Primary Hyperoxaluria Market Drivers

• Current and Future Changes in the Paradigm of Therapies – Entry of Approved Therapy, Future Potentials of Emerging Treatment
• Increasing Prevalence
• Global Exposure

Scope of the Primary Hyperoxaluria Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Primary Hyperoxaluria Companies: Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, and others
• Key Primary Hyperoxaluria Therapies: Nedosiran (DCR-PHXC), ALLN-177, Stiripentol, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Primary Hyperoxaluria Unmet Needs, KOL’s views, Analyst’s views, Primary Hyperoxaluria Market Access and Reimbursement 

Primary Hyperoxaluria Market Barriers

• Lack of Available Long-term Data
• Delayed Diagnosis
• Challenges in terms of management
• Lack of Robust Pipeline

Table of Contents 

1. Primary Hyperoxaluria Market Report Introduction

2. Executive Summary for Primary Hyperoxaluria

3. SWOT analysis of Primary Hyperoxaluria

4. Primary Hyperoxaluria Patient Share (%) Overview at a Glance

5. Primary Hyperoxaluria Market Overview at a Glance

6. Primary Hyperoxaluria Disease Background and Overview

7. Primary Hyperoxaluria Epidemiology and Patient Population

8. Country-Specific Patient Population of Primary Hyperoxaluria 

9. Primary Hyperoxaluria Current Treatment and Medical Practices

10. Primary Hyperoxaluria Unmet Needs

11. Primary Hyperoxaluria Emerging Therapies

12. Primary Hyperoxaluria Market Outlook

13. Country-Wise Primary Hyperoxaluria Market Analysis (2019–2032)

14. Primary Hyperoxaluria Market Access and Reimbursement of Therapies

15. Primary Hyperoxaluria Market Drivers

16. Primary Hyperoxaluria Market Barriers

17.  Primary Hyperoxaluria Appendix

18. Primary Hyperoxaluria Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Primary Hyperoxaluria treatment, visit @ Primary Hyperoxaluria Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services